Compound: Entinostat
SMILES: O=C(OCc1cnccc1)NCc2ccc(C(=O)Nc3c(N)cccc3)cc2
InChIKey: INVTYAOGFAGBOE-UHFFFAOYSA-N
Synonyms: Entinostat, 209783-80-2, ms-275, SNDX-275, MS 275, MS-27-275, SNDX 275, MS 27-275, entinostatum, 1ZNY4FKK9H, BAY 86-5274, N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate, NSC706995, BAY86-5274, Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester, MS-275-27, DTXSID0041068, CHEBI:132082, (pyridin-3-yl)methyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate, pyridin-3-ylmethyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester, N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide, pyridin-3-ylmethyl N-((4-((2-aminophenyl)carbamoyl)phenyl)methyl)carbamate, (pyridin-3-yl)methyl N-((4-((2-aminophenyl)carbamoyl)phenyl)methyl)carbamate, N-((4-((2-aminoanilino)-oxomethyl)phenyl)methyl)carbamic acid 3-pyridinylmethyl ester, CARBAMIC ACID, N-((4-(((2-AMINOPHENYL)AMINO)CARBONYL)PHENYL)METHYL)-, 3-PYRIDINYLMETHYL ESTER, RefChem:590863, HDAC inhibitor SNDX-275, DTXCID8021068, L01XX64, N-(2-Aminophenyl)-4-(N-(pyridin-3-yl-methoxycarbonyl)aminomethyl)b enzamide, 630-693-0, Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl) methyl)-, 3-pyridinylmethyl ester, Entinostat (MS-275), pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate, MFCD08272435, CHEMBL27759, (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate, s1053, NSC-706995, pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate, pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate, 3-pyridylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate, 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate, Carbamic acid, N-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- pyridinylmethyl ester, Entinostat(MS-27-275), 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]carbamate, Entinostat, free base, ENTINOSTAT [INN], ENTINOSTAT [JAN], Entinostat [USAN:INN], UNII-1ZNY4FKK9H, ENTINOSTAT [USAN], Entinostat (MS-275)?, benzamide-type inhibitor, 3, Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester, ENTINOSTAT [WHO-DD], MLS006010183, Entinostat (JAN/USAN/INN), SCHEMBL148309, Entinostat (MS-27-275), TNFa + MS-275, GTPL7007, orb1300954, SCHEMBL29387345, SCHEMBL29499905, SCHEMBL29838042, BDBM19410, EX-A038, GLXC-04607, HMS3426G07, HMS3648K12, HMS3654O11, HMS3744O17, HMS5079K07, pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate., EBC-11304, HB3983, NSC756642, Entinostat (MS-275;SNDX-275), [4-(2-Amino-phenylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester, AKOS024262667, N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide, AC-8968, Carbamic acid, 3-pyridinylmethyl ester, CCG-208680, CS-0511, DB11841, Entinostat (MS-275, SNDX-275), FE15194, NSC 706995, NSC-756642, SB16665, Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester, N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester, NCGC00165833-01, NCGC00165833-02, NCGC00165833-03, NCGC00165833-04, NCGC00165833-11, NCGC00165833-13, AS-17906, BP-25653, HY-12163, NCI60_038022, SMR004458705, SY067823, MS-275, A HDAC1 and HDAC3 inhibitor, ZK 244894, E1454, NS00068485, SW219667-1, D09338, EN300-6488260, MS-275,Entinostat, SNDX-275, MS-27-275, SR-01000946382, Q1281020, SR-01000946382-1, BRD-K77908580-001-02-1, BRD-K77908580-001-04-7, BRD-K77908580-001-09-6, BRD-K77908580-001-10-4, Z2037280922, pyridin-3-ylmethyl4-((2-aminophenyl)carbamoyl)benzylcarbamate, (Pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate, Pyridin-3-ylmethyl ({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate, N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]-3-pyridinylmethyl ester, carbamic acid
Theoretical properties:
molecular_formula: C21H20N4O3
molecular_weight: 376.4 g/mol
exact_mass: 376.15354051 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 3
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 7
heavy_atom_count: 28
topological_polar_surface_area: 106 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Entinostat is a member of the class of benzamides resulting from the formal condensation of the carboxy group of the pyridin-3-ylmethyl carbamate derivative of p-(aminomethyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an inhibitor of histone deacetylase isoform 1 (HDAC1) and isoform 3 (HDAC3). It has a role as an antineoplastic agent, an EC 3.5.1.98 (histone deacetylase) inhibitor and an apoptosis inducer. It is a member of benzamides, a carbamate ester, a member of pyridines, a substituted aniline and a primary amino compound. It is functionally related to a 1,2-phenylenediamine.
chebi: A member of the class of benzamides resulting from the formal condensation of the carboxy group of the pyridin-3-ylmethyl carbamate derivative of <em>p</em>-(aminomethyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an inhibitor of histone deacetylase isoform 1 (HDAC1) and isoform 3 (HDAC3).
chembl: ENTINOSTAT is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.
Entinostat inhibits class I HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively.
Syndax pharmaceuticals currently holds the rights to entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.
It has also been investigated as a potential male contraceptive drug.